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A new method is described for performing hydrogen/deuterium (H/D) exchange in an
electrospray ionization (ESI) source. The use of liquid chromatography (LC)-mass spectrom-
eter equipped with an ESI source and deuterium oxide (D2O) as the sheath liquid allows H/D
exchange experiments to be performed on-line. This directly provides information for
determining the number and position of exchangeable hydrogens, aiding in the elucidation of
the structures of drug metabolites. To demonstrate the utility of this method, LC-mass
spectrometry (MS) and LC-MS/MS experiments were performed using either H2O or D2O as
sheath liquid on a matrix metalloprotease (MMP) inhibitor (PD 0200126) and its metabolites.
Examination of the mass shift of the deuteriated molecule from that of the protonated molecule
allowed the number of exchangeable protons to be determined. Interpretation of the product-
ion-spectra helped to determine the location of the exchanged protons and assisted in the
assignment of the site(s) of modification for each metabolite. (J Am Soc Mass Spectrom 2002,
13, 345–353) © 2002 American Society for Mass Spectrometry
During the process of drug discovery, it is highlydesirable to increase the number of successfuldrug candidates for preclinical, clinical and
commercial development. Therefore, the drug discov-
ery process is constantly scrutinized and improved [1].
Adding to this pressure is the generation of vast num-
bers of new chemical entities resulting from combina-
torial chemistry technology [2]. Drug metabolism plays
an important role in the drug discovery process [3].
Specifically, the identification of metabolites during the
early stage of development can be helpful to medicinal
chemists trying to block some of the metabolic hot spots
and produce an appropriate drug that is less susceptible
to metabolism and increase the half-life of the drug.
Therefore, rapid identification of drug metabolites is
imperative for drug development [4, 5].
Hydrogen/deuterium exchange is a well-established
technique for studying structure, stability, folding dy-
namics, and intermolecular interactions in proteins in
solution [6]. During solution phase H/D exchange,
labile protons in the side chains and amide hydrogens,
which are not protected from solution generally ex-
change rapidly. Exchanges of these unprotected hydro-
gens occur on the order of a few to a few tenths per
second under the experimental conditions described in
the aforementioned studies. If however, amide or side
chain hydrogens are protected from solution (e.g., when
they are hydrogen-bonded in structurally stable sec-
ondary-structure elements), the exchange rates can be
considerably reduced. Methods in which H/D ex-
change experiments are combined with either nuclear
magnetic resonance (NMR) spectroscopy or mass spec-
trometry are also well-established [7, 8]. NMR methods,
when coupled with H/D exchange are the ideal choice
for monitoring individual residues or each amide hy-
drogen; however, these methods are limited to highly
purified proteins or metabolites that are soluble at high
concentrations, thus eliminating the possibility of deter-
mining structural features of drugs and metabolites that
are in the discovery stage of drug development and are
only available in limited quantities. On the contrary,
mass spectrometry methods have advantages from in-
herent sensitivity and selectivity.
As early as 1971, Hunt et al. [9] showed that under
chemical ionization (CI) conditions, H/D exchange
can be rapidly achieved by using either CH3OD or
ND3 as reagent gas. Later, Hunt and Sethi [10]
showed that the proton affinity difference between
the analyte and the reagent gas is a major factor in
determining the degree of exchange in chemical
ionization mass spectrometry. Isotopic exchange
studies performed in a collision cell of a tandem mass
spectrometer was used to show that CH3OD ex-
changed specific acidic hydrogens of phenols and
carboxylic acids but not the amino hydrogens [11].
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Gas-phase H/D exchange kinetics of several proton-
ated amino acids and dipeptides have also been
reported [12]. Although limited, H/D exchange reac-
tions have been used in the structural studies in
combination with fast atom bombardment (FAB) [13],
Frit-FAB [14], and thermospray [15, 16] ionization
techniques.
Hydrogen/deuterium exchange studies involving
ESI produced ions are relatively new. Its feasibility was
originally demonstrated by Katta and Chait [17, 18]
when they showed that charge state distribution of
proteins in ESI mass spectra, to some extent, reflect the
amount of protonation of proteins in solution and ESI
spectra can be used to study conformational changes of
proteins in solution. Later, this technique was extended
to quality control studies involving recombinant pro-
tein drugs [19], chaperonian protein folding [20], li-
gand-binding studies [21], and for screening combina-
torial libraries of de novo proteins [22]. In addition,
H/D exchange methods have also been expanded to
study conformational differences of multiply proton-
ated gas-phase proteins [23].
Aforementioned methods, however, are not suitable
for accommodating the needs of the pharmaceutical
industry because during the drug discovery process,
rapid and sensitive on-line methods are required for
identification of the metabolites. In an attempt to
achieve this, Hemling et al. [24] used ND3 as the
nebulizer or curtain gas and showed the feasibility of
H/D exchange for structure elucidation of ESI formed
ions. Demonstration of this method, however, was
limited to infusion of purified sample into a mass
spectrometer. Furthermore, the usefulness of this
method for obtaining tandem mass spectrometry infor-
mation was not demonstrated. Recently, Liu et al. [25]
and Ohashi et al. [26] used deuterium oxide as the LC
mobile phase to enable on-line H/D exchange experi-
ments to facilitate drug metabolite identification. This
technique, however, required preparation of all the
samples in D2O and using all deuteriated buffer and
mobile phase which in turn lacks the practical utility
for rapid metabolite identification. To date, a practi-
cal ESI based on-line H/D exchange or similar
method for characterization of drug metabolites re-
main unknown.
In this paper, we describe our experimental effort in
achieving on-line type H/D exchange for characteriza-
tion of metabolites of a matrix metalloprotease (MMP)
inhibitor (PD 0200126). MMP are a class of zinc contain-
ing enzymes that are responsible for the degradation of
extracellular matrix components such as collagen. Al-
though the role of MMP is not completely understood,
they are implicated in a wide range of vascular diseases,
including inflammation, smooth muscle cell migration,
and the pathogenesis of vascular lesions [27]. LC-
ESI-MS and LC-ESI-MS/MS spectra obtained on an ion
trap mass spectrometer using either H2O or D2O as
sheath liquid were compared to aid in identification of
the metabolites of PD 0200126.
Experimental
[14C]PD 0200126, 2-(4-bromo-biphenyl-4-sulfonylami
no)-N-hydroxy-3-methyl-butyramide [27] and the pro-
posed metabolites M8 (PD 0408208), M9 (PD 0169469),
and M10 (PD 0307442) were synthesized at Pfizer Global
Research & Development (Ann Arbor, MI) and con-
firmed by NMR, LC-MS, and LC-MS/MS [27].
In Vivo Study
Blood collected at various time points following a 300
mg/kg oral administration of PD 0200126 to rabbits was
used to obtain plasma samples. Plasma was precipi-
tated by addition of three volumes of acetonitrile to one
volume of plasma and then centrifuging and transfer-
ring the supernatant and drying it down. The dried
sample was reconstituted in mobile phase and a 100-uL
aliquot was injected for each experiment. Details of the
in vivo experiment are described elsewhere [28].
In Vitro Study: HPLC and MS Conditions
The proposed metabolite M2 (PD 0200126-glucuronide)
was formed following incubation of [14C]PD 0200126
with dog liver hepatocytes for 180 min and the incuba-
tion conditions have been described [28].
HPLC grade solvents were purchased from Mallink-
rodt Baker, Inc. (Paris, KY). Water was purified using
the Millipore Milli-Qplus water purification system
(Bedford, MA). Ultima Flo M scintillation cocktail was
purchased from Packard Instrument Co. (Meridan, CT).
A 2.0 ng/L stock solution of PD 0200126 was prepared
in methanol, and 200 ng of each analyte standard was
injected for analysis.
The HPLC system consisted of Agilent 1100 (Agilent
Technologies, Wilmington, DE) pumps with an Agilent
1100 autoinjector and a UV detector. Separation of
metabolites was achieved using a Metasil AQ guard
column (Metachem Technologies, Torrance, CA) and a
150  4.6 mm MetaChem Polaris C-18 reversed-phase
HPLC column (Metachem Technologies). The mobile
phase, which consisted of 20 mM ammonium acetate in
water adjusted to pH 4 with acetic acid (Solvent A) and
acetonitrile (Solvent B), was maintained at a constant
flow rate (1 mL/min). Gradient elution of metabolites
was achieved using programmed stepwise changes of
A/B ratios starting at 95/5, 50/50, 25/75, 5/95, and
95/5 at 0, 40, 50, 60, and 75 min, respectively. After
passing through the UV detector (280 nm), the HPLC
effluent was split so that 20–30% of the flow was
introduced into the mass spectrometer via the supplied
ESI source while 70–80% was diverted to the radioac-
tivity detector. The analog output from the UV and
radioactivity detector, along with the MS signal were
recorded in real time by the data system provided with
the mass spectrometer (Xcalibur V 1.2, Thermo Finni-
gan). A separate software program (Win-Flow V 1.5,
IN/US, Tampa, FL) was used to control the -RAM and
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also collect the analog output from the -RAM and the
-RAM data was integrated to obtain semi-quantitative
information about the metabolites and the unchanged
drug. The delay in response between the radioactivity
detector and MS was 0.2-0.4 min with the MS response
being recorded first.
Sheath liquid, either H2O or D2O, was delivered at a
constant flow rate of 0.2 or 0.4 mL/min by a PE Series
200 pump (Perkin Elmer, Norwalk, CT) (Figure 1).
LC-MS (scan range 100–1100 Da) and LC-MS/MS ex-
periments were performed using an ion trap (LCQ-
Deca, Thermo Finnigan, San Jose, CA) mass spectrom-
eter equipped with an ESI ion source. Operating
conditions for ESI in the negative ionization mode were
as follows: spray voltage, 4500 V; capillary temperature,
300 °C; sheath gas (N2), 80 (arbitrary units); and auxil-
iary gas (N2), 20 (arbitrary units). For all LC-MS/MS
experiments performed using the ion trap mass spec-
trometer, helium was maintained at a constant pressure
of 40 psi and used as the damping gas as well as the
collision gas. For all LC-MSn experiments, the precursor
isolation window was set at 1 Thompson and the
activation amplitude (%), activation Q, and activation
time (ms) were set at 35, 0.25, and 30, respectively.
Generally, 10–15 scans were signal averaged to obtain a
final MS or MS/MS spectrum.
Results and Discussion
The structures of all the drug candidates and the
metabolites studied as well as the maximum number of
exchangeable hydrogens associated with each of the
chemical entities are listed in Table 1. Structure eluci-
dation of these metabolites was achieved by full scan
LC-MS and MS/MS with and without hydrogen/deu-
terium exchange. Under the LC-MS conditions used,
PD 0200126 eluted at 38.6 min and deprotonated mol-
ecules ([M  H]) containing 79Br and 81Br were de-
tected at m/z 425 and 427, respectively (Figure 2 bottom
panel). When D2O was used as the sheath liquid at a
flow rate of 0.2 mL/min, the most abundant isotopic
envelope was observed to shift by 2 Da to m/z 427 and
429 (Figure 2 middle panel). The most intense peak in
the mass spectrum, m/z 427, was associated with re-
placement of the maximum number of exchangeable
protons (i.e., hydrogens on heteroatoms such as O, N,
and S) and associated removal of a deuterium for
ionization. Although ions of m/z 427 and 429 are abun-
dant among the isotopic cluster ions observed, detec-
tion of ions of m/z 426 and 428 indicated that the
exchange has not been driven to completion. Absence
or presence of negligible amounts of ions of m/z 425
following the H/D exchange (Figure 2 middle panel)
suggests that PD 0200126 is undergoing exchange to
replace at least two of the three active hydrogens. As
explained by Palmer et al. [29] during a similar H/D
exchange experiment involving CE-MS, incomplete ex-
change can be associated with either the rate of the
exchange or back-exchange. In other words, if the
exchangeable hydrogens are not equally active, only the
most active hydrogen will undergo the exchange. Thus,
making the process rate limiting. On the other hand,
back-exchange can also contribute to incomplete ex-
change because of the presence of H2O in solvents or
inadequate amounts of D2O.
To explore these two factors associated with incom-
plete hydrogen/deuterium exchange and how they
influence structural elucidation, we undertook system-
atic evaluation of the sheath liquid H/D exchange
process. Our first evaluation was around the sheath
liquid flow rate. Increasing the sheath liquid flow rate
from 0.2 to 0.4 mL/min increased the theoretical atom
% of deuterium in the ESI source from 62 % (0.2/(0.125
 0.2), where 0.125 is the estimated flow of aqueous
buffer entering the source at40 min and 0.2 is the D2O
sheath liquid flow rate) to 76 % (0.4/(0.125  0.4)) [30]
and resulted in limited change on the isotopic cluster
pattern. However, reducing the sheath liquid flow rate
to 0.1 mL/min completely shifted the isotopic cluster
pattern and gave a nearly Gaussian distribution of
peaks. To confirm the experimental % D incorporation
and to compare with the theoretical values of 62–76%
and to calculate the number exchangeable hydrogens,
we used the step-by-step method described by McClo-
skey et al. [30, 31]. The mass spectrum of PD 0200126
obtained before exchange (Figure 2) showed m/z 425,
426, 427, 428, and 429 peaks to have relative intensities
(%) of 39.3, 8.2, 41.1, 8.5, and 2.9, respectively. Following
in-ion-source exchange, the isotopic cluster ions of m/z
425, 426, 427, 428, 429, 430, and 431 were detected with
respective relative intensities (%) of 1.1, 10.7, 33.3, 14.6,
32.8, 5.9, and 1.6. Our calculations using the method
described by McCloskey and co-workers [30, 31]
showed that PD 0200126 underwent two exchanges and
the experimentally determined % D incorporation to be
less than 50%. Although the calculations were complex
due to the presence of multiisotopic elements, results
show that in-source H/D exchange is most likely lim-
ited by the % of deuterium available for the exchange
and rate limited.
To further assess the effect of exchange rate and back
Figure 1. Schematic showing the instrumental setup used for the
in ESI source H/D exchange.
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exchange, we incubated 200 L of the PD 0200126
standard with 800 L of D2O for 24 h and used
deuteriated mobile phase along with D2O sheath liquid
and repeated the LC-MS experiment. Isotopic cluster
pattern (Figure 2 top panel) with less abundant ions of
m/z 426 indicated that the exchange has been driven to
near completion compared to previous experiments
where the H/D exchange was limited to occur only in
the ion source region. Additionally, this experiment
confirmed that in-source sheath liquid H/D exchange is
less efficient than off-line solvent exchange. However,
compared to previously described on-line type H/D
exchange methods [25, 26] using in-source H/D ex-
change, information about the exchangeable hydrogens
of the metabolites can be readily made available.
Next, we evaluated the use of in-ion-source H/D
exchange for structure elucidation of the metabolites.
Initial experiments were performed using mobile phase
system (HPLC flow rate of 1 mL/min) consisted of 20
mM ammonium acetate in water adjusted to pH 4 with
acetic acid (Solvent A) and acetonitrile (Solvent B) and
the sheath liquid (0.2 mL/min) was either H2O or D2O.
This set of experiments limited the hydrogen/deute-
rium exchange to take place only in the ion source
region. A comparison of the product-ion-spectra ob-
tained using H2O and D2O as sheath liquid is shown
(Figure 3 bottom and middle panels). The next set of
experiments was performed using mobile phase system
(HPLC flow rate of 1 mL/min) consisting of 20 mM
ammonium acetate in H2O or D2O adjusted to pH 4
Max-Ex: Maximum Number of Exchangeable Protons
*Highest molecular ion pair of the molecular ion cluster.
Table 1. List of metabolites, the corresponding number of exchangeable protons associated with each metabolite, deprotonated and
dedeuteriated ion cluster information
Figure 2. A comparison of LC-MS spectra of PD 0200126 stan-
dard obtained using off-line H/D exchange followed by HPLC
using deuteriated mobile phase and D2O as the sheath liquid (top
panel), on-line H/D exchange using aqueous mobile phase and
D2O as the sheath liquid (middle panel), and aqueous mobile
phase and H2O as the sheath liquid (bottom panel).
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with acetic acid (Solvent A) and acetonitrile (Solvent B)
and respectively H2O or D2O as the sheath liquid at a
flow rate of 0.2 mL/min. This set of experiments
allowed the hydrogen/deuterium exchange to occur
before injection on the column and increased the % D
incorporation by the use of D2O as the mobile phase
(Figure 3 top panel). Comparison of the middle and top
panels of Figure 3 clearly shows that H/D exchange has
not been driven to completion in the in ESI ion source
H/D exchange process. Presence of fragment ions of
m/z 249, 297, 312, and 382 indicates that some of the
precursor ions of m/z 427 that got isolated for MS/MS
are from 81Br-PD 0200126 and the presence of abundant
ions of m/z 247, 295, 311, and 380 indicates that most of
the m/z 427 that got selected for MS/MS are from
79Br-PD 0200126 that had undergone three deuterium
exchanges (net gain of two due to removal of an
exchangeable proton for ionization). The shift of the
fragment ion of m/z 310 (Figure 3 bottom panel) to m/z
311 (Figure 3 middle and top panels) clearly shows that
the amide nitrogen on the bromo-biphenyl-sulfonamide
moiety is intact. Absence of the fragment ions of m/z
249, 297, 312, and 382 in the MS/MS spectrum obtained
following off-line H/D exchange for 24 h (Figure 3 top
panel) clearly indicates that H/D exchange has been
driven to completion and under the experimental con-
ditions used % D available was much higher than
62–76% deuterium made available for the in-ion- source
exchange experiments. In addition, the back exchange
was limited or absent in solvent exchange method
(off-line). However, this method is labor intensive and
not practical when rapid information is required for
early identification of the metabolites. To further con-
firm the fragmentation assignment and to examine if
the lower H/D exchange efficiency associated with
in-ion-source exchange can cause any difficulties with
product ion interpretation, deprotonated molecules that
contained 81Br that had undergone three exchanges
(less one exchangeable proton due to ionization) were
selected and subjected to tandem mass spectrometry.
Upon CID, the precursor ion of m/z 429 formed frag-
ment ions of 249, 297, and 312. Unlike the in-ion-source
H/D exchange product ion spectrum of 79Br-PD
0200126, the in-ion-source H/D exchange product ion
spectrum of 81Br-PD 0200126 was less complex (Figure
4 middle panel) and matched very closely the product
ion spectrum obtained following off-line solution phase
H/D exchange (Figure 4 top panel). A 2 Da mass shift
of the fragment ions following the H/D exchange
confirmed the fragmentation assignment (Figures 3 and
4 middle and top panel).
To evaluate the sensitivity and demonstrate the
validity of this approach at the early drug discovery
stage, we tested the method using rabbit plasma ex-
tracts. As shown in Figure 5, rabbit plasma showed
three prominent UV components associated with me-
tabolites M7, M8 and M9, respectively, at m/z 425, 310,
and 410 (metabolites M1–M6 were characterized in a
separate study involving rat and mouse hepatocytes).
Trace amounts of PD 0200126 and M10 were also
observed at m/z 425 and 409, respectively. Structure
elucidation of these metabolites was achieved by the
combined use of LC-MS and LC-MS/MS where H2O
was used as both an aqueous component of the mobile
phase and sheath liquid while conducting in-ion-source
H/D exchange experiments.
Metabolite M7
Metabolite M7 which had a similar nominal mass as the
parent drug (Figure 5), eluted at 36.1 min. The odd
Figure 3. A comparison of LC-MS/MS spectra of PD 0200126
standard (MS isolation of deprotonated molecules that contained
79Br) obtained using off-line H/D exchange followed by HPLC
using deuteriated mobile phase and D2O as the sheath liquid (top
panel), on-line H/D exchange using aqueous mobile phase and
D2O as the sheath liquid (middle panel), and aqueous mobile
phase and H2O as the sheath liquid (bottom panel).
Figure 4. A comparison of LC-MS/MS spectra of PD 0200126
standard (MS isolation of deprotonated molecules that contained
81Br) obtained using off-line H/D exchange followed by HPLC
using deuteriated mobile phase and D2O as the sheath liquid (top
panel), on-line H/D exchange using aqueous mobile phase and
D2O as the sheath liquid (middle panel), and aqueous mobile
phase and H2O as the sheath liquid (bottom panel).
349J Am Soc Mass Spectrom 2002, 13, 345–353 IN ELECTROSPRAY IONIZATION SOURCE H/D EXCHANGE
value of m/z for the metabolite M7 ion indicates that M7
bears an even number of nitrogen atoms. When H2O
was used as the sheath liquid, M7 showed similar
isotopic cluster pattern as the parent, however, when
subjected to H/D exchange, the isotopic cluster pattern
of M7 was different from that of the parent drug. As
shown in Figure 2, when PD 0200126 was subjected to
H/D exchange, the most abundant isotopic cluster ion
shifted by 2 Da whereas with M7 a 3 Da shift was
observed (Figure 6). For metabolite M7, a 3 Da increase
is in agreement with the presence of four exchangeable
hydrogens in the proposed monohydroxy-PD 0200126-
amide or monohydroxy-PD 0307442 structure. Under
the LC-MS/MS conditions used, M7 showed similar
fragmentation pattern as the parent except with differ-
ent relative abundance (Figure 7 bottom panel). The
major fragment ion at m/z 297 suggested that the
bromo-biphenyl-4-sulfonyl moiety is intact. Fragment
ion at m/z 312 suggested that the bromo-biphenyl-4-
sulfonylamino moiety is also intact and modification,
possibly hydroxylation, is taking place on the 3-methyl-
butyramide moiety. Unlike the parent, metabolite M7
underwent fragmentation to give abundant fragment
ions corresponding to [M-H-SO2]
 at m/z 363. Where a
similar fragmentation behavior is observed with metab-
olite M10 (PD 0307442) or PD 0200126-amide (MS/MS
spectrum not provided). Thus suggesting that this me-
tabolite is possibly a monohydroxylated derivative of
PD 0200126-amide. In addition to showing the fragment
ions present in the MS/MS spectrum of the parent
(Figure 7 bottom panel), M7 also gave trace amounts of
fragment ion corresponding to [M-H-H2O]
 at m/z 409.
This fragment ion further supported the structural
assignment provided for metabolite M7.
Additionally, post H/D exchange MS/MS spectrum
of the precursor ions of m/z 430 clearly supports the
proposed structure for metabolite M7 (Figure 7 top and
middle panels). As shown in the fragmentation scheme,
the major fragment ion at m/z 297 suggests that the
bromo-biphenyl-4-sulfonyl moiety is intact. Fragment
ions at m/z 313/314 suggest that the bromo-biphenyl-4-
sulfonylamino moiety is intact and confirms the pres-
ence of an exchangeable hydrogen. As expected, the
fragment ion at m/z 363 corresponding to [M-H-SO2]

shifted by 3 Da to m/z 366. Both the H/D exchange
information and the product-ion-spectra suggest that
M7 is a metabolite where isopropyl moiety of PD
0307442 is modified by hydroxylation. As shown in the
fragmentation scheme (Figure 7), observation of the
fragment ion at m/z 352 and the associated deuterium
exchanged fragment ion at m/z 353 suggests that hy-
Figure 5. Extracted ion chromatograms for PD 0200126, M7, M8,
M9, and M10 obtained using plasma following an oral administra-
tion of 300 mg/kg of PD 0200126 to rabbits.
Figure 6. A comparison of LC-MS spectra of M7 metabolite
obtained using off-line H/D exchange followed by HPLC using
deuteriated mobile phase and D2O as the sheath liquid (top panel),
on-line H/D exchange using aqueous mobile phase and D2O as
the sheath liquid (middle panel), and aqueous mobile phase and
H2O as the sheath liquid (bottom panel).
Figure 7. A comparison of LC-MS/MS spectra of metabolite M7
(MS isolation of deprotonated molecules that contained 81Br)
obtained using off-line H/D exchange followed by HPLC using
deuteriated mobile phase and D2O as the sheath liquid (top panel),
on-line H/D exchange using aqueous mobile phase and D2O as
the sheath liquid (middle panel), and aqueous mobile phase and
H2O as the sheath liquid (bottom panel).
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droxylation is most likely occurring on the methyl
portion of the isopropyl moiety.
Metabolite M8
Metabolite M8 eluted at 40.2 min (Figure 5) and gave
deprotonated molecule that contained 79Br and 81Br
respectively at m/z 310 and 312. The even value of m/z
for the metabolite M8 ion indicates that M8 bears an odd
number of nitrogen atoms. Under the MS/MS condi-
tions used, precursor ions of m/z 310 fragmented to give
ions of m/z 246 corresponding to [M-H-SO2]
 (MS/MS
spectrum not shown). Similarly, precursor ions of m/z
312 fragmented to give ions of m/z 248 corresponding to
[M-H-SO2]
 (MS/MS spectrum not shown). Loss of 64
Da suggested that sulfone is part of the metabolite and
the fragment ion of m/z 248 suggested that bromo-
biphenylamide is intact. Following ESI source H/D
exchange, the molecular ion cluster shifted from 310/
312 to 311/313 and confirmed the presence of an
exchangeable hydrogen. Based on this information a
structure of bromo-biphenylsulfonamide was proposed
for metabolite M8 (Table 1). Finally, the proposed struc-
ture was confirmed by synthesis of reference standard
(PD 0408208). The retention time, electrospray mass
spectrum, and the tandem mass spectrum of the syn-
thetic standard was in close agreement with that ob-
tained from the metabolite M8 formed in vitro and in
vivo.
Metabolite M9
Metabolite M9 eluted at 40.9 min and gave deproto-
nated molecule that contained 79Br and 81Br respec-
tively at m/z 410 and 412. The even value of m/z for the
metabolite M9 ion indicates that M9 bears an odd
number of nitrogen atoms. Precursor ions of m/z 410
fragmented to give ions of m/z 247, 295, and 310 (Figure
8 bottom panel). The fragment ions of m/z 295 and 310
suggested that bromo-biphenylsulfonyl and bromo-bi-
phenylsulfonylamino moieties are intact, respectively.
Most likely, the fragment ion at m/z 247 is associated
with [295-SO]. Based on these MS/MS data and the
molecular weight information, a structure of PD
0200126-carboxylic acid was proposed. To confirm the
structural assignment, H2O and D2O were used sepa-
rately as the sheath liquid and LC-MS and MS/MS data
were collected. In addition to the molecular ion cluster
at m/z 410/412 (H2O sheath) and 411/413 (D2O sheath),
409/411 (H2O sheath) and 410/412 (D2O sheath) were
also observed in the LC-MS spectra. The latter two pairs
are most likely originating from combination of the
following: Co-eluting metabolite M10, co-eluting metab-
olite undergoing a single deuterium exchange and some
unexchanged M9. When D2O was used as the sheath
liquid, the majority of the molecular ion cluster from M9
shifted by 1 Da to 411/413. Increment of a Da is in
agreement with the proposed structure of PD 0200126-
carboxylic acid where two exchangeable hydrogens are
present and one is removed for ionization. To further
confirm the structural assignment, LC-MS/MS spectra
were collected separately using H2O and D2O as the
sheath liquid (Figure 8). Presence of ions of m/z 247 and
295 in both spectra plainly shows that bromo-biphenyl-
sulfonyl moiety is intact. Mass shift of the fragment ion
at m/z 310 to 311 clearly suggests the presence of an
exchangeable hydrogen and the amide moiety of bro-
mo-biphenylsulfonamide is intact. The retention time,
electrospray mass spectrum, and the tandem mass
spectrum of the synthetic standard (PD 0169469) was in
close agreement with that obtained from the metabolite
M9 formed in vitro and in vivo.
Metabolite M10
Metabolite M10, a minor UV component in the rabbit
plasma, eluted at 41.0 min and showed deprotonated
molecule that contained 79Br and 81Br respectively at
m/z 409 and 411. The odd value of m/z for the metabolite
M10 ion indicates that M10 bears an even number of
nitrogen atoms. Molecular weight of 410, correspond-
ing to a decrease of 16 Da over the molecular weight of
PD 0200126 suggests that metabolite M10 is most likely
an amide metabolite. Comparison of the product ion
spectrum of M10 with that of PD 0200126 reference
standard and presence of product ions of m/z 295 and
310 suggested that bromo-biphenylsulfonyl and bromo-
biphenylsulfonylamino moieties are intact, respectively
(MS/MS spectrum not shown). Unlike the parent or the
carboxylic acid metabolite, M10 undergoes fragmenta-
tion to give abundant ions corresponding to [M-H-
SO2]
 at m/z 345. To confirm the structural assignment,
in-ion-source H/D exchange experiment was carried
out on this metabolite. The molecular ion cluster was
observed to shift by 2 Da to 411/413 and indicated the
presence of three exchangeable hydrogens. Upon CID,
the precursor ion of m/z 411 gave fragment ions of m/z
295, 311, and 347 and confirmed the structural assign-
ment. Finally, the retention time, electrospray mass
spectrum, and the tandem mass spectrum of the syn-
Figure 8. A comparison of LC-MS/MS spectra of metabolite M9
obtained using H2O (bottom panel) and D2O (top panel) as the
sheath liquid.
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thetic standard (PD 0307442) were in close agreement
with that obtained from the metabolite M10 formed in
vitro and in vivo.
The next set of experiments were carried out to
verify if the in-ion-source H/D exchange is limited to
Phase I modifications or modification by addition of
1–4 exchangeable hydrogens and is applicable to phase
II modification such as glucuronidation which will
result in addition of more than five exchangeable hy-
drogens. This set of experiments also demonstrated that
the in-ion-source H/D exchange is applicable not only
to discovery (non-radiolabeled parent drug) metabolite
identification but also to development studies (radiola-
beled parent drug).
Metabolite M2
Following incubation of [14C]PD 0200126 with dog
hepatocytes for 180 min (Figure 9), the major radioac-
tive component representing more than 90 % of the total
radioactivity was associated with PD 0200126-glucuro-
nide (M2) and minor amounts of the radioactivity was
associated with M9. As shown in Figure 9, when sub-
jected to in-ion-source H/D exchange the molecular ion
cluster observed at m/z 601/603 shifted to give ions at
m/z 602, 603, 604, 605, 606, 607, and 608. Similarly, [M 
2H  Na] ions at m/z 623/625 shifted to 624, 625, 626,
627, 628, and 629. Presence of ions of m/z 606/608
clearly show that all six exchangeable hydrogens (with
one removed for forming the ion) in PD 0200126-
glucuronide are available for exchange and the precur-
sors for these ions are most likely ions of m/z 601/603.
Formation of the sodium adduct results in the removal
of a second proton or deuterium and results in one less
exchangeable hydrogen. These observations clearly
show that M2 is a glucuronide conjugate of PD 0200126
and not a conjugate of M7. If M2 had been a glucuronide
conjugate of M7, seven exchangeable hydrogens would
be available for the exchange reaction. The proposed
structure of M2 was further confirmed by -glucuroni-
dase hydrolysis experiments [28]. Structure elucidation
of M2 further confirmed that the in-ion-source H/D
exchange is not limited to phase I type biotransforma-
tion where the metabolic addition of exchangeable
hydrogens is limited and the experimental set-up is not
limited to discovery type metabolite identification stud-
ies and it will allow one to obtain structural information
as well as radioactivity quantitative information (using
the split-flow technique) about the metabolites.
Conclusions
The use of mass spectrometer equipped with an ESI
source and deuterium oxide (D2O) as the sheath liquid
for performing on-line H/D exchange experiments has
been demonstrated. Experiments show that when using
in-ion-source H/D exchange the exchange efficiencies
are not high as samples dissolved in D2O and the use of
D2O mobile phase, the method described in this paper
can be used to rapidly identify the number of exchange-
able hydrogens of drugs and metabolites and to char-
acterize them.
H/D exchange experiments allowed us to distin-
guish the parent drug from metabolite M7, which had
the same nominal mass and identical elemental compo-
sition. In addition, presence of the bromine atom, spe-
cifically the unique isotopic cluster distribution, in the
parent drug allowed us to assess the effectiveness of the
in-ion-source H/D exchange for obtaining tandem mass
spectrometry information. Comparison of the product-
ion-spectra obtained using the precursor ions formed
following in-ion-source H/D exchange and solution
(off-line) H/D exchange with deuteriated mobile phase
shows that structure elucidation of metabolites can be
achieved by using precursor ions where the H/D ex-
change has not been driven to completion. Our experi-
ments also show that in-ion-source H/D exchange is
not limited to metabolites formed by addition of smaller
number of exchangeable hydrogens such as the ones
associated with Phase I biotransformation but also to
Phase II biotransformation which usually results in
metabolites formed by addition of five or more ex-
changeable hydrogens (glucuronidation and glutathi-
one but not sulfation). Thus, by using in-ion-source
H/D exchange, some of the unambiguous metabolite
identification, which can be very useful in the early
stages of drug discovery, can be achieved without the
use of large scale preparation for NMR or LC-NMR or
performing solvent (off-line) H/D exchange involving
the use of deuteriated mobile phase.
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